Collaboration at the Forefront

Pharmaceutical CommercePharmaceutical Commerce - August 2023
Volume 18
Issue 4

As Pharma Commerce continues to increase its conference exposure, it all could not have been possible without the help of colleagues.

Nicholas Saraceno

Nicholas Saraceno

Pharmaceutical Commerce’s parent company, MJH Life Sciences®, preaches several mantras to its employees, but one that has always stood out to me was that “collaboration saves lives.” While sounding straightforward, the phrase hammers home the importance of teamwork, whether that be internally—with colleagues—or externally—with the men and women we cover in this industry on a daily basis. This became much clearer to me after attending the DIA Global Annual Meeting in Boston in late June.

Readers will notice that I dive into certain aspects of my experiences in this issue’s “Conference Connect,” but I would like to take a moment to recognize the efforts of my colleagues spanning multiple brands and departments, including:

•Todd Baker, VP of pharmaceutical sciences
•Lisa Henderson, our group editorial director for Pharmaceutical Commerce,
Pharmaceutical Executive, Applied Clinical Trials, and Medical Device & Technology
•Andy Studna, editor of Applied Clinical Trials
•Miranda Schmalfuhs, group social media editor for all four brands
•Kate Baker, marketing manager for all four brands

At the DIA event, these individuals were essential in helping to coordinate interviews, making sure they all came together from a logistical standpoint, “dividing and conquering” when it came to attending the multitude of educational sessions, and helping to facilitate new connections for future editorial coverage.

Speaking of upcoming coverage and topics, the Pharma Commerce team has been diligently working to construct next year’s media kit, which will feature a revamped editorial calendar and new areas of focus. I look forward to sharing more information on this in the coming months.

In other news, as I write this, more and more details are being released regarding a tornado that struck a Pfizer manufacturing facility in Rocky Mount, NC, which according to multiple reports, supplies nearly 30% of sterile injectables to US hospitals. There had previously been a rumor that this plant contained Pfizer’s COVID-19 vaccine, but that has since been dispelled. We wish them a quick rebuild!

Nicholas Saraceno is Pharmaceutical Commerce's Editor. He can be reached at [email protected].

Related Content
© 2024 MJH Life Sciences

All rights reserved.